Continuous Mixing of Solid Dosage Forms via Hot-Melt Extrusion - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Continuous Mixing of Solid Dosage Forms via Hot-Melt Extrusion
The author describes the benefits, processes, and practicality of using hot-melt extrusion to mix active pharmaceutical ingredients with pharmaceutical-grade polymers.


Pharmaceutical Technology
Volume 32, Issue 10, pp. 76-86




Now we can calculate the SE:

in which SE is denoted in kw per kg/h, kw is kilowatts (the motor rating, kw = hp x 0.746); % torque is the percentage used of the maximum allowable torque; and rpm is the screws' rotations per minute. A lower SE indicates that less mechanical energy is being used, and a larger SE indicates more energy. SE records are particularly important to confirm batch-to-batch consistency, as well as for troubleshooting and scale-up purposes.

Scale-up. Scale-up is useful for estimating rates for production twin-screw extruders based on lab experiments. When comparing different size extruders, the geometries should be nearly identical for this equation to be valid. For processes that scale-up volumetrically, the equation is as follows:

Scale up – Power based: Q target = Q reference [(ODtarget)/ODreference)]3

in which Q is the throughput rate (in any units) and OD is the screw outside diameter (each). The greater the difference in OD, the less reliable this calculation becomes. Accuracy is also dependent upon whether the process is restricted by a volume, heat transfer, or mass transfer limitation. For a heat-transfer limited process, the exponent is closer to 2.0. For mass-transfer limited processes, the scale-up exponent is typically between 2.3 and 2.7 (as compared to 3.0).

For rough scaling between different-size machines that share geometric similarities (OD/ID ratio and similar screw designs) the comparative free volumes are a useful benchmark. For instance:

Q target = Q reference (Volumetarget/Volumereference)

For example, assuming geometric similarities, if an 18 mm twin-screw extruder has a SV of 3 cc/dia and is running at 2 kg/h, then it can be inferred that a 30 mm extruder with a specific volume (SV) of 12 cc/dia will process approximately four times the rate, or 8 kg/h.

Residence time. This formula provides the approximate residence time (RT) in the process section of an HSEI twin-screw extruder. As denoted above, the residence time distribution is highly dependent upon the degree of screw fill. The following equation can be used for RT:

RT(s) = (SV SG L/D %fill)/(Q 0.2777)

where RT is residence time in seconds, SV is specific volume in cc/dia, SG is specific gravity, L/D is the L/D extruder ratio, % fill is the degree of fill expressed as a decimal (i.e., 40% = 0.4), and Q is the kg/h being processed. The RT formula provides insight as to how long materials are exposed to heat and shear in the process section.

Temperature rise during pressure generation. Pressure generation in the front end of the extruder caused by the die restriction results in a temperature rise. The more restrictive the front end, the higher the pressure and melt temperature rise, which may adversely effect the product. The temperature rise equation is as follows:

Δ T (C) = Δ P (bar) / 2


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here